Scrutiny of the Co-Cytotoxic Impact of Metformin-Omeprazole on the Cervical Cancer Cell Line and Their Aptitude to Target Heat Shock 60
Abstract
OBJECTIVE: This study aimed to assess the simultaneous effect of the metformin-omeprazole combination on inhibiting cervical cancer proliferation. Their ability to target heat shock protein 60.
METHODS: The anticancer properties of the metformin-omeprazole combination in cancer treatment were evaluated by employing a cervical cancer cell line (HeLa cell line). The assessment included two incubation periods: one of 24 hours and another of 72 hours. The concentrations of metformin, omeprazole, and their combination varied from 0.1 to 1000 µg/ml. The study encompassed an estimated combination index value to assess the potential synergistic effect of metronidazole and linagliptin. The study employs computational molecular docking simulation to determine the affinity of metformin and omeprazole for binding with heat shock protein 60.
RESULTS: The study concluded that the metformin-omeprazole combination significantly reduced the proliferation of cervical cancer cells. The inhibitory effect was demonstrated to depend on the mixture's concentration and the treatment duration. The combination index indicates that metformin and omeprazole synergistically interacted. furthermore, the computational molecular docking simulation indicated that metformin and omeprazole exhibited a propensity to associate with Hsp 60. The docking scores for metformin and omeprazole were measured at -7.3 kcal/mol and -6.2 kcal/mol, respectively.
CONCLUSION: Study indicates that the simultaneous use of…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.